Shukra Pharmaceuticals (524632) Q4 23/24 earnings summary

Executive summary

• FY24 revenue from operations rose to ₹7,457.29 lakh from ₹5,883.37 lakh; profit after tax increased to ₹1,853.72 lakh from ₹440.65 lakh.

• Operations included pharmaceutical manufacturing and trading, laboratory testing, and product exports; management described the business as undergoing restructuring and targeting improved turnover.

Financial highlights

• Total income was ₹7,738.81 lakh vs ₹6,003.04 lakh; other income increased to ₹281.52 lakh from ₹119.67 lakh.

• Profit before tax was ₹1,988.33 lakh vs ₹444.17 lakh; total tax expense was ₹134.61 lakh vs ₹3.51 lakh.

• Profit after tax was ₹1,853.72 lakh vs ₹440.65 lakh; total comprehensive income was ₹1,853.72 lakh vs ₹439.71 lakh.

• Reported profit before interest, depreciation, amortization and tax was ₹1,988.33 lakh vs ₹656.00 lakh.

Outlook and guidance

• Directors were optimistic about business prospects and expected higher revenue and improved performance in subsequent years.

• Management cited operational excellence initiatives to optimize costs and delivery, a strong year-end cash-flow position, and plans to pursue growth initiatives.

• Outlook highlighted a sophisticated injectable plant, continuous improvement, and ambitions for broader international market reach.